Pamela Munster, MD

Professor
Department of Medicine
[email protected]
[email protected]
Primary Thematic Area: 
Cancer Biology & Cell Signaling
Secondary Thematic Area: 
None
Publications: 

Characterizing safety, toxicity, and breast cancer risk reduction using a long-term fulvestrant eluting implant.

Scientific reports

Thomas S, Roche E, Desai P, Pawlowska N, Bauer D, Gingrich D, Hsu E, Deitchman AN, Aweeka F, Munster PN

Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors.

Breast cancer research : BCR

Pacaud R, Thomas S, Chaudhuri S, Lazar A, Timmerman LA, Munster PN

A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies.

European journal of cancer (Oxford, England : 1990)

Ribrag V, Iglesias L, De Braud F, Ma B, Yokota T, Zander T, Spreafico A, Subbiah V, Illert AL, Tan D, Santoro A, Munster PN, Suehiro Y, Wang Y, Ji DM, Chen S, Beltz K, Suenaga N, Ramkumar T, Luo F, Lai C, Wainberg ZA

Estrogens and breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology

Kim J, Munster PN

Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies.

JCO precision oncology

Tsang ES, Aggarwal RR, Bergsland EK, Calabrese S, Rozie A, Chaudhuri S, Dhawan MS, Pawlowska N, Grabowsky J, Thomas S, Munster PN